A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Ir-CPI in Healthy Male Subjects

NCT04653766 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

32

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy

Interventions

DRUG: Ir-CPI - Dose 1
DRUG: Ir-CPI - Dose 2
DRUG: Ir-CPI - Dose 3
DRUG: Ir-CPI - Dose 4
DRUG: Placebo

Sponsor

Bioxodes S.A.